Dr. Jeremy Abramson, MD
Claim this profileMassachusetts General Hospital
Area of expertise
Non-Hodgkin's Lymphoma
Jeremy Abramson, MD has run 8 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
B-Cell Lymphoma
Jeremy Abramson, MD has run 7 trials for B-Cell Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Massachusetts General Hospital
Massachusetts General Hospital / Dana-Farber Cancer Institute
Clinical Trials Jeremy Abramson, MD is currently running
GM T Cell Therapy Long-Term Follow-Up
for Cancer
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting
1 award
Phase 2 & 3
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting
1 award
Phase 2
5 criteria
More about Jeremy Abramson, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Jeremy Abramson, MD has experience with
- Nivolumab
- UCART20x22
- Doxorubicin
- Brentuximab Vedotin
- Dacarbazine
- JCAR017 (lisocabtagene Maraleucel) Single-dose Schedule
Breakdown of trials Jeremy Abramson, MD has run
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Follicular Lymphoma
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeremy Abramson, MD specialize in?
Jeremy Abramson, MD focuses on Non-Hodgkin's Lymphoma and B-Cell Lymphoma. In particular, much of their work with Non-Hodgkin's Lymphoma has involved MYC positive patients, or patients who are BCL2 positive.
Is Jeremy Abramson, MD currently recruiting for clinical trials?
Yes, Jeremy Abramson, MD is currently recruiting for 4 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Jeremy Abramson, MD has studied deeply?
Yes, Jeremy Abramson, MD has studied treatments such as Nivolumab, UCART20x22, Doxorubicin.
What is the best way to schedule an appointment with Jeremy Abramson, MD?
Apply for one of the trials that Jeremy Abramson, MD is conducting.
What is the office address of Jeremy Abramson, MD?
The office of Jeremy Abramson, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02114 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.